Valbenazine for Tardive Dyskinesia.

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Tardive dyskinesia (TD) is a persistent concern for patients on antipsychotic medications.
• Despite newer agents having lower risk, long-term antipsychotic use frequently leads to TD.
• Valbenazine (Ingrezza) is the first FDA-approved medication specifically for TD treatment.

Purpose of the Study:

• To review the pharmacology and clinical trial data of valbenazine for TD treatment.
• To assess the efficacy and safety profile of valbenazine.
• To compare valbenazine with existing treatments like tetrabenazine.

Main Methods:

• Review of basic pharmacology of valbenazine.
• Analysis of short-term clinical trial results for valbenazine.
• Comparison of valbenazine's characteristics with tetrabenazine.

Main Results:

• Valbenazine at 80 mg/day demonstrated a clinically significant improvement in TD (d=0.90).
• The 40 mg/day dose showed a lower effect size (d=0.52).
• Valbenazine offers advantages over tetrabenazine, including once-daily dosing and a better short-term side effect profile.

Conclusions:

• Valbenazine represents a significant advancement in TD treatment.
• Further long-term studies are needed to fully understand its benefits and risks in real-world clinical settings.
• Optimal dosing and long-term safety require ongoing investigation.